Literature DB >> 26530262

The role of imaging in the management of adults with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.

Sarah Jost Fouke1, Tammie Benzinger2, Daniel Gibson3, Timothy C Ryken4, Steven N Kalkanis5, Jeffrey J Olson6.   

Abstract

QUESTION: What is the optimal imaging technique to be used in the diagnosis of a suspected low grade glioma, specifically: which anatomic imaging sequences are critical for most accurately identifying or diagnosing a low grade glioma (LGG) and do non-anatomic imaging methods and/or sequences add to the diagnostic specificity of suspected low grade gliomas? TARGET POPULATION: These recommendations apply to adults with a newly diagnosed lesion with a suspected or histopathologically proven LGG. LEVEL II: In patients with a suspected brain tumor, the minimum magnetic resonance imaging (MRI) exam should be an anatomic exam with both T2 weighted and pre- and post-gadolinium contrast enhanced T1 weighted imaging. CRITICAL IMAGING FOR THE IDENTIFICATION AND DIAGNOSIS OF LOW GRADE GLIOMA: LEVEL II: In patients with a suspected brain tumor, anatomic imaging sequences should include T1 and T2 weighted and Fluid Attenuation Inversion Recovery (FLAIR) MR sequences and will include T1 weighted imaging after the administration of gadolinium based contrast. Computed tomography (CT) can provide additional information regarding calcification or hemorrhage, which may narrow the differential diagnosis. At a minimum, these anatomic sequences can help identify a lesion as well as its location, and potential for surgical intervention. IMPROVEMENT OF DIAGNOSTIC SPECIFICITY WITH THE ADDITION OF NON-ANATOMIC (PHYSIOLOGIC AND ADVANCED IMAGING) TO ANATOMIC IMAGING: LEVEL II: Class II evidence from multiple studies and a significant number of Class III series support the addition of diffusion and perfusion weighted MR imaging in the assessment of suspected LGGs, for the purposes of discriminating the potential for tumor subtypes and identification of suspicion of higher grade diagnoses. LEVEL III: Multiple series offer Class III evidence to support the potential for magnetic resonance spectroscopy (MRS) and nuclear medicine methods including positron emission tomography and single-photon emission computed tomography imaging to offer additional diagnostic specificity although these are less well defined and their roles in clinical practice are still being defined. QUESTION: Which imaging sequences or parameters best predict the biological behavior or prognosis for patients with LGG? TARGET POPULATION: These recommendations apply to adults with a newly diagnosed lesion with a suspected or histopathologically proven LGG. RECOMMENDATION: Anatomic and advanced imaging methods and prognostic stratification LEVEL III: Multiple series suggest a role for anatomic and advanced sequences to suggest prognostic stratification among low grade gliomas. Perfusion weighted imaging, particularly when obtained as a part of diagnostic evaluation (as recommended above) can play a role in consideration of prognosis. Other imaging sequences remain investigational in terms of their role in consideration of tumor prognosis as there is insufficient evidence to support more formal recommendations as to their use at this time. QUESTION: What is the optimal imaging technique to be used in the follow-up of a suspected (or biopsy proven) LGG? TARGET POPULATION: This recommendation applies to adults with a newly diagnosed low grade glioma. LEVEL II: In patients with a diagnosis of LGG, anatomic imaging sequences should include T2/FLAIR MR sequences and T1 weighted imaging before and after the administration of gadolinium based contrast. Serial imaging should be performed to identify new areas of contrast enhancement or significant change in tumor size, which may signify transformation to a higher grade. LEVEL III: Advanced imaging utility may depend on tumor subtype. Multicenter clinical trials with larger cohorts are needed. For astrocytic tumors, baseline and longitudinal elevations in tumor perfusion as assessed by dynamic susceptibility contrast perfusion MRI are associated with shorter time to tumor progression, but can be difficult to standardize in clinical practice. For oligodendrogliomas and mixed gliomas, MRS may be helpful for identification of progression.

Entities:  

Keywords:  Diagnostic specificity; Guidelines; Low grade glioma; Magnetic resonance imaging; Prognosis

Mesh:

Year:  2015        PMID: 26530262     DOI: 10.1007/s11060-015-1908-9

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  73 in total

1.  Cerebral blood volume measurements and proton MR spectroscopy in grading of oligodendroglial tumors.

Authors:  M Vittoria Spampinato; J Keith Smith; Lester Kwock; Matthew Ewend; John D Grimme; Daniel L A Camacho; Mauricio Castillo
Journal:  AJR Am J Roentgenol       Date:  2007-01       Impact factor: 3.959

2.  MR diffusion tensor and perfusion-weighted imaging in preoperative grading of supratentorial nonenhancing gliomas.

Authors:  Xiang Liu; Wei Tian; Balasubramanya Kolar; Gabrielle A Yeaney; Xing Qiu; Mahlon D Johnson; Sven Ekholm
Journal:  Neuro Oncol       Date:  2011-02-04       Impact factor: 12.300

3.  Histologically confirmed changes on CT of reoperated low-grade astrocytomas.

Authors:  D Afra; E Osztie
Journal:  Neuroradiology       Date:  1997-11       Impact factor: 2.804

4.  5-year survival and clinical prognostic factors in progressive supratentorial diffuse "low-grade" astrocytoma: a retrospective analysis of 46 cases.

Authors:  P R Schuurman; D Troost; B Verbeeten; D A Bosch
Journal:  Acta Neurochir (Wien)       Date:  1997       Impact factor: 2.216

5.  MR imaging of adult supratentorial astrocytomas: an attempt of semi-automatic grading.

Authors:  F Mihara; Y Numaguchi; M Rothman; S Sato; M S Fiandaca
Journal:  Radiat Med       Date:  1995 Jan-Feb

6.  Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected].

Authors:  Michael H Lev; Yelda Ozsunar; John W Henson; Amjad A Rasheed; Glenn D Barest; Griffith R Harsh; Markus M Fitzek; E Antonio Chiocca; James D Rabinov; Andrew N Csavoy; Bruce R Rosen; Fred H Hochberg; Pamela W Schaefer; R Gilberto Gonzalez
Journal:  AJNR Am J Neuroradiol       Date:  2004-02       Impact factor: 3.825

Review 7.  Management of low-grade glioma.

Authors:  Nader Pouratian; David Schiff
Journal:  Curr Neurol Neurosci Rep       Date:  2010-05       Impact factor: 5.081

8.  Predicting the histopathological grade of cerebral gliomas using high b value MR DW imaging at 3-tesla.

Authors:  Juan Alvarez-Linera; Julián Benito-León; Jose Escribano; G Rey
Journal:  J Neuroimaging       Date:  2008-05-05       Impact factor: 2.486

9.  Relative cerebral blood volume measurements of low-grade gliomas predict patient outcome in a multi-institution setting.

Authors:  Gisele B Caseiras; Sophie Chheang; James Babb; Jeremy H Rees; Nicole Pecerrelli; Daniel J Tozer; Christopher Benton; David Zagzag; Glyn Johnson; Adam D Waldman; H R Jäger; Meng Law
Journal:  Eur J Radiol       Date:  2009-02-06       Impact factor: 3.528

10.  Supratentorial low-grade astrocytoma. Correlation of computed tomography findings with effect of radiation therapy and prognostic variables.

Authors:  Y Shibamoto; Y Kitakabu; M Takahashi; J Yamashita; Y Oda; H Kikuchi; M Abe
Journal:  Cancer       Date:  1993-07-01       Impact factor: 6.860

View more
  32 in total

Review 1.  Guidelines in the management of CNS tumors.

Authors:  Navid Redjal; Andrew S Venteicher; Danielle Dang; Andrew Sloan; Remi A Kessler; Rebecca R Baron; Constantinos G Hadjipanayis; Clark C Chen; Mateo Ziu; Jeffrey J Olson; Brian V Nahed
Journal:  J Neurooncol       Date:  2021-02-21       Impact factor: 4.130

2.  Preoperative grading of supratentorial nonenhancing gliomas by high b-value diffusion-weighted 3 T magnetic resonance imaging.

Authors:  Haiwei Han; Chengkun Han; Xiurong Wu; Shan Zhong; Xiongjie Zhuang; Guowei Tan; Hua Wu
Journal:  J Neurooncol       Date:  2017-04-24       Impact factor: 4.130

3.  Imaging growth as a predictor of grade of malignancy and aggressiveness of IDH-mutant and 1p/19q-codeleted oligodendrogliomas in adults.

Authors:  Alexandre Roux; Arnault Tauziede-Espariat; Marc Zanello; Sophie Peeters; Gilles Zah-Bi; Eduardo Parraga; Myriam Edjlali; Emmanuèle Lechapt; Natalia Shor; Luisa Bellu; Giulia Berzero; Didier Dormont; Edouard Dezamis; Fabrice Chretien; Catherine Oppenheim; Marc Sanson; Pascale Varlet; Laurent Capelle; Frédéric Dhermain; Johan Pallud
Journal:  Neuro Oncol       Date:  2020-07-07       Impact factor: 12.300

Review 4.  Technical principles in glioma surgery and preoperative considerations.

Authors:  Daria Krivosheya; Sujit S Prabhu; Jeffrey S Weinberg; Raymond Sawaya
Journal:  J Neurooncol       Date:  2016-06-17       Impact factor: 4.130

5.  Pseudo-insular glioma syndrome: illustrative cases.

Authors:  Alexander F Haddad; Jacob S Young; Ramin A Morshed; S Andrew Josephson; Soonmee Cha; Mitchel S Berger
Journal:  J Neurosurg Case Lessons       Date:  2021-12-27

6.  What matters for people with brain cancer? Selecting clinical quality indicators for an Australian Brain Cancer Registry.

Authors:  Misa Matsuyama; Mythily Sachchithananthan; Robyn Leonard; Michael Besser; Anna K Nowak; Donna Truran; Claire M Vajdic; John R Zalcberg; Hui K Gan; Craig Gedye; Winny Varikatt; Eng-Siew Koh; Ganessan Kichenadasse; Hao-Wen Sim; Nicholas G Gottardo; Desma Spyridopoulos; Rosalind L Jeffree
Journal:  Neurooncol Pract       Date:  2021-08-31

7.  Demonstration of DCE-MRI as an early pharmacodynamic biomarker of response to VEGF Trap in glioblastoma.

Authors:  Allison F O'Neill; Lei Qin; Patrick Y Wen; John F de Groot; Annick D Van den Abbeele; Jeffrey T Yap
Journal:  J Neurooncol       Date:  2016-08-30       Impact factor: 4.130

8.  Visual and semiquantitative 11C-methionine PET: an independent prognostic factor for survival of newly diagnosed and treatment-naïve gliomas.

Authors:  Nina Poetsch; Adelheid Woehrer; Johanna Gesperger; Julia Furtner; Alexander R Haug; Dorothee Wilhelm; Georg Widhalm; Georgios Karanikas; Michael Weber; Ivo Rausch; Markus Mitterhauser; Wolfgang Wadsak; Marcus Hacker; Matthias Preusser; Tatjana Traub-Weidinger
Journal:  Neuro Oncol       Date:  2018-02-19       Impact factor: 12.300

9.  Interval brain imaging for adults with cerebral glioma.

Authors:  Gerard Thompson; Theresa A Lawrie; Ashleigh Kernohan; Michael D Jenkinson
Journal:  Cochrane Database Syst Rev       Date:  2019-12-24

10.  Interventions to reduce the time to diagnosis of brain tumours.

Authors:  Robin Grant; Therese Dowswell; Eve Tomlinson; Paul M Brennan; Fiona M Walter; Yoav Ben-Shlomo; David William Hunt; Helen Bulbeck; Ashleigh Kernohan; Tomos Robinson; Theresa A Lawrie
Journal:  Cochrane Database Syst Rev       Date:  2020-09-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.